Sun Pharma Advanced Research Company (SPARC) was locked in 20% upper circuit at Rs 161.10 after the company announced that the U.S. District Court has granted summary judgement in favour of SPARC for Sezaby PRV.
In a regulatory filing made during market hours today, the company stated that the U.S. District Court for the District of Columbia granted summary judgment in favour of SPARC in the matter of issuance of priority review voucher (PRV) associated with the approval of Sezaby.
The Court granted SPARCs motion for summary judgment and held that FDAs withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was previously approved as that term is used in the statute and allowed 60 days to appeal against the motion.
Anil Raghavan, CEO, SPARC, said: We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARCs long held position on this matter.
SEZABY is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures.
Also Read
 "Vice-Admiral K Swaminathan")
 "Stock Market LIVE, December 2, 2025")
 "WHO infertility guideline")
 "H1B visa")
 "Israel Flag, Israel")
Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.
The company had reported a consolidated net loss of Rs 75.85 crore in the quarter ended September 2025 as against net loss of Rs 107.33 crore during the previous quarter ended September 2024. Sales declined 38.88% to Rs 7.86 crore in Q2 FY26 over Q2 FY25.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
